Drug Patents owned by Biomarin Pharm

1. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring Nov, 2024

(2 years from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin Nov, 2024

(2 years from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin May, 2025

(2 years from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring May, 2025

(2 years from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

US7566462 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

US8003126 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

US7566462

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

US8003126

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin Nov, 2032

(10 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Treatment: To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

2. Drug name - VOXZOGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8198242 BIOMARIN PHARM Variants of C-type natriuretic peptide
Jun, 2030

(7 years from now)

CN102481330B BIOMARIN PHARM C-Type Natriuretic Peptide Variants
May, 2030

(7 years from now)

CN102481330A BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

IN391651B BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

IN201109124P1 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

EP3175863A1 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

EP3175863B1 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

EP2432489A4 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

EP2432489A2 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

EP2432489B1 BIOMARIN PHARM Variants Of C-Type Natriuretic Peptide
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48267 BIOMARIN PHARM Variants of C-type natriuretic peptide May, 2030

(7 years from now)

US10646550 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug, 2036

(13 years from now)

US9907834 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug, 2036

(13 years from now)

Drugs and Companies using VOSORITIDE ingredient

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/VIAL POWDER;SUBCUTANEOUS Prescription
0.56MG/VIAL POWDER;SUBCUTANEOUS Prescription
1.2MG/VIAL POWDER;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.